Synaptogenix, Inc. financial data

Symbol
SNPX on Nasdaq
Location
1185 Avenue Of The Americas, 3 Rd Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
NEUROTROPE BIOSCIENCE, INC. (to 11/20/2020)
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 568 % -56.6%
Debt-to-equity 61.8 % +262%
Return On Equity -85.8 % -282%
Return On Assets -51.9 % -187%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.39M shares -94.9%
Common Stock, Shares, Outstanding 1.36M shares +40.9%
Entity Public Float 6.62M USD 0%
Common Stock, Value, Issued 137 USD +42.7%
Weighted Average Number of Shares Outstanding, Basic 1.23M shares +165%
Weighted Average Number of Shares Outstanding, Diluted 1.23M shares +165%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.6M USD -19%
General and Administrative Expense 5.21M USD -17.8%
Nonoperating Income (Expense) -5.96M USD -362%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -12.8M USD -111%
Net Income (Loss) Attributable to Parent -12.8M USD -111%
Earnings Per Share, Basic 11 USD/shares -62.8%
Earnings Per Share, Diluted 4.58 USD/shares +445%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.7M USD -38.4%
Assets, Current 17.7M USD -42%
Property, Plant and Equipment, Net 12.9K USD -30.2%
Assets 17.7M USD -43%
Accounts Payable, Current 317K USD -28.6%
Accrued Liabilities, Current 697K USD +59.9%
Liabilities, Current 1.01M USD -76.3%
Liabilities 11M USD +98.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 5.7K USD +532%
Retained Earnings (Accumulated Deficit) -47.2M USD -40.3%
Stockholders' Equity Attributable to Parent 5.86M USD -75.9%
Liabilities and Equity 17.7M USD -43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.83M USD -8%
Net Cash Provided by (Used in) Investing Activities -500K USD -24434%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 1.36M shares +40.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.7M USD -38.4%
Deferred Tax Assets, Valuation Allowance 33M USD +9.19%
Payments to Acquire Property, Plant, and Equipment 2.04K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -13.6M USD +1.63%
Deferred Tax Assets, Operating Loss Carryforwards 29.2M USD +9.46%
Preferred Stock, Shares Authorized 1M shares 0%
Additional Paid in Capital 53M USD -8.51%
Depreciation, Depletion and Amortization 1.4K USD -17.2%
Share-based Payment Arrangement, Expense 25.4K USD -97.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%